Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 418

1.

[Corrigendum] Death receptor 5 expression is inversely correlated with prostate cancer progression.

Hernandez-Cueto A, Hernandez-Cueto D, Antonio-Andres G, Mendoza-Marin M, Jimenez-Gutierrez C, Sandoval-Mejia AL, Mora-Campos R, Gonzalez-Bonilla C, Vega MI, Bonavida B, Huerta-Yepez S.

Mol Med Rep. 2017 Oct;16(4):5738. doi: 10.3892/mmr.2017.7234. Epub 2017 Aug 11.

2.

Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma.

Shvartsur A, Givechian KB, Garban H, Bonavida B.

J Exp Clin Cancer Res. 2017 May 5;36(1):62. doi: 10.1186/s13046-017-0535-z. Review.

3.

Crosstalks between Raf-kinase inhibitor protein and cancer stem cell transcription factors (Oct4, KLF4, Sox2, Nanog).

Lee S, Wottrich S, Bonavida B.

Tumour Biol. 2017 Apr;39(4):1010428317692253. doi: 10.1177/1010428317692253. Review.

PMID:
28378634
4.

Inverse correlation between the metastasis suppressor RKIP and the metastasis inducer YY1: Contrasting roles in the regulation of chemo/immuno-resistance in cancer.

Wottrich S, Kaufhold S, Chrysos E, Zoras O, Baritaki S, Bonavida B.

Drug Resist Updat. 2017 Jan;30:28-38. doi: 10.1016/j.drup.2017.01.001. Epub 2017 Jan 9. Review.

PMID:
28363333
5.

The Forgotten YY2 in Reported YY1 Expression Levels in Human Cancers.

Kaufhold S, Aziz N, Bonavida B.

Crit Rev Oncog. 2017;22(1-2):63-73. doi: 10.1615/CritRevOncog.2017020475.

PMID:
29604937
6.

Targeting the Overexpressed YY1 in Cancer Inhibits EMT and Metastasis.

Cho AA, Bonavida B.

Crit Rev Oncog. 2017;22(1-2):49-61. doi: 10.1615/CritRevOncog.2017020473.

PMID:
29604936
7.

Therapeutic YY1 Inhibitors in Cancer: ALL in ONE.

Bonavida B.

Crit Rev Oncog. 2017;22(1-2):37-47. doi: 10.1615/CritRevOncog.2017020472.

PMID:
29604935
8.

Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Bonavida B, Chouaib S.

Ann Oncol. 2017 Mar 1;28(3):457-467. doi: 10.1093/annonc/mdw615. Review.

9.

Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.

Suzuki E, Umezawa K, Bonavida B.

Oncogene. 2016 Oct 20;35(42):5576. doi: 10.1038/onc.2016.207. Epub 2016 Jun 27. No abstract available.

PMID:
27345401
10.

Yin Yang 1 is associated with cancer stem cell transcription factors (SOX2, OCT4, BMI1) and clinical implication.

Kaufhold S, Garbán H, Bonavida B.

J Exp Clin Cancer Res. 2016 May 25;35:84. doi: 10.1186/s13046-016-0359-2. Review.

11.

Correlation between the overexpression of Yin Yang 1 and the expression levels of miRNAs in Burkitt's lymphoma: A computational study.

Hafsi S, Candido S, Maestro R, Falzone L, Soua Z, Bonavida B, Spandidos DA, Libra M.

Oncol Lett. 2016 Feb;11(2):1021-1025. Epub 2015 Dec 14.

12.

Activation of Natural Killer Cells by Probiotics.

Aziz N, Bonavida B.

For Immunopathol Dis Therap. 2016;7(1-2):41-55. doi: 10.1615/ForumImmunDisTher.2016017095.

13.

P38 MAPK expression and activation predicts failure of response to CHOP in patients with Diffuse Large B-Cell Lymphoma.

Vega GG, Avilés-Salas A, Chalapud JR, Martinez-Paniagua M, Pelayo R, Mayani H, Hernandez-Pando R, Martinez-Maza O, Huerta-Yepez S, Bonavida B, Vega MI.

BMC Cancer. 2015 Oct 16;15:722. doi: 10.1186/s12885-015-1778-8.

14.

Special collection: Nitric oxide in cancer.

Muntané J, Bonavida B.

Redox Biol. 2015 Dec;6:505-6. doi: 10.1016/j.redox.2015.09.038. Epub 2015 Sep 25. No abstract available.

15.

Nitric oxide-mediated sensitization of resistant tumor cells to apoptosis by chemo-immunotherapeutics.

Bonavida B, Garban H.

Redox Biol. 2015 Dec;6:486-94. doi: 10.1016/j.redox.2015.08.013. Epub 2015 Aug 18. Review.

16.

Overcoming rituximab drug-resistance by the genetically engineered anti-CD20-hIFN-α fusion protein: Direct cytotoxicity and synergy with chemotherapy.

Vega GG, Franco-Cea LA, Huerta-Yepez S, Mayani H, Morrison SL, Bonavida B, Vega MI.

Int J Oncol. 2015 Nov;47(5):1735-48. doi: 10.3892/ijo.2015.3170. Epub 2015 Sep 16.

17.

Dual roles of nitric oxide in the regulation of tumor cell response and resistance to photodynamic therapy.

Rapozzi V, Della Pietra E, Bonavida B.

Redox Biol. 2015 Dec;6:311-7. doi: 10.1016/j.redox.2015.07.015. Epub 2015 Jul 31. Review.

18.

The Role Of Nitric Oxide After Repeated Low Dose Photodynamic Treatments In Prostate Carcinoma Cells.

Rapozzi V, Pietra ED, Bonavida B, Xodo LE.

Redox Biol. 2015 Aug;5:422-423. doi: 10.1016/j.redox.2015.09.037. Epub 2015 Dec 30.

19.

Regulation Of Cell Death Apoptotic Pathways By Nitric Oxide In Cancer: Reversal Of Drug/Immune Resistance.

Bonavida B.

Redox Biol. 2015 Aug;5:415. doi: 10.1016/j.redox.2015.09.016. Epub 2015 Dec 30.

20.

Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.

Shvartsur A, Bonavida B.

Genes Cancer. 2015 Mar;6(3-4):84-105. Review.

21.

Repeated sub-optimal photodynamic treatments with pheophorbide a induce an epithelial mesenchymal transition in prostate cancer cells via nitric oxide.

Della Pietra E, Simonella F, Bonavida B, Xodo LE, Rapozzi V.

Nitric Oxide. 2015 Feb 15;45:43-53. doi: 10.1016/j.niox.2015.02.005. Epub 2015 Feb 17.

PMID:
25700664
22.

Prognostic significance of YY1 protein expression and mRNA levels by bioinformatics analysis in human cancers: a therapeutic target.

Bonavida B, Kaufhold S.

Pharmacol Ther. 2015 Jun;150:149-68. doi: 10.1016/j.pharmthera.2015.01.011. Epub 2015 Jan 23. Review.

PMID:
25619146
24.

Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance.

Bonavida B.

Semin Oncol. 2014 Oct;41(5):667-77. doi: 10.1053/j.seminoncol.2014.08.006. Epub 2014 Aug 12. Review.

25.

Death receptor 5 expression is inversely correlated with prostate cancer progression.

Hernandez-Cueto A, Hernandez-Cueto D, Antonio-Andres G, Mendoza-Marin M, Jimenez-Gutierrez C, Sandoval-Mejia AL, Mora-Campos R, Gonzalez-Bonilla C, Vega MI, Bonavida B, Huerta-Yepez S.

Mol Med Rep. 2014 Nov;10(5):2279-86. doi: 10.3892/mmr.2014.2504. Epub 2014 Aug 21.

26.

Central role of Snail1 in the regulation of EMT and resistance in cancer: a target for therapeutic intervention.

Kaufhold S, Bonavida B.

J Exp Clin Cancer Res. 2014 Aug 2;33:62. doi: 10.1186/s13046-014-0062-0. Review.

27.
28.

Overexpression of Yin Yang 1 in bone marrow-derived human multiple myeloma and its clinical significance.

Huerta-Yepez S, Liu H, Baritaki S, Del Lourdes Cebrera-Muñoz M, Rivera-Pazos C, Maldonado-Valenzuela A, Valencia-Hipolito A, Vega MI, Chen H, Berenson JR, Bonavida B.

Int J Oncol. 2014 Sep;45(3):1184-92. doi: 10.3892/ijo.2014.2511. Epub 2014 Jun 20.

PMID:
24970600
29.
30.

Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer.

Yousuf S, Duan M, Moen EL, Cross-Knorr S, Brilliant K, Bonavida B, LaValle T, Yeung KC, Al-Mulla F, Chin E, Chatterjee D.

PLoS One. 2014 Mar 21;9(3):e92478. doi: 10.1371/journal.pone.0092478. eCollection 2014.

31.

Roles Each of Snail, Yin Yang 1 and RKIP in the Regulation of Tumor Cells Chemo-immuno-resistance to Apoptosis.

Bonavida B, Jazirehi A, Vega MI, Huerta-Yepez S, Baritaki S.

For Immunopathol Dis Therap. 2013;4(1). doi: 10.1615/ForumImmunDisTher.2013008299.

32.

Expression of KLF4 is a predictive marker for survival in pediatric Burkitt lymphoma.

Valencia-Hipόlito A, Hernández-Atenógenes M, Vega GG, Maldonado-Valenzuela A, Ramon G, Mayani H, Peña Alonso Y, Martinez-Maza O, Méndez-Tenorio A, Huerta-Yepez S, Bonavida B, Vega MI.

Leuk Lymphoma. 2014 Aug;55(8):1806-14. doi: 10.3109/10428194.2013.848437. Epub 2014 Feb 6.

PMID:
24067139
33.

Galiximab (anti-CD80)-induced growth inhibition and prolongation of survival in vivo of B-NHL tumor xenografts and potentiation by the combination with fludarabine.

Hariharan K, Chu P, Murphy T, Clanton D, Berquist L, Molina A, Ho SN, Vega MI, Bonavida B.

Int J Oncol. 2013 Aug;43(2):670-6. doi: 10.3892/ijo.2013.1986. Epub 2013 Jun 13.

34.

Nitric oxide-mediated activity in anti-cancer photodynamic therapy.

Rapozzi V, Della Pietra E, Zorzet S, Zacchigna M, Bonavida B, Xodo LE.

Nitric Oxide. 2013 Apr 1;30:26-35. doi: 10.1016/j.niox.2013.01.002. Epub 2013 Jan 26.

PMID:
23357401
35.

Contribution of either YY1 or BclXL-induced inhibition by the NO-donor DETANONOate in the reversal of drug resistance, both in vitro and in vivo. YY1 and BclXL are overexpressed in prostate cancer.

Huerta-Yepez S, Baritaki S, Baay-Guzman G, Hernandez-Luna MA, Hernandez-Cueto A, Vega MI, Bonavida B.

Nitric Oxide. 2013 Feb 28;29:17-24. doi: 10.1016/j.niox.2012.12.001. Epub 2012 Dec 11.

PMID:
23246440
36.

HIF-1 expression is associated with CCL2 chemokine expression in airway inflammatory cells: implications in allergic airway inflammation.

Baay-Guzman GJ, Bebenek IG, Zeidler M, Hernandez-Pando R, Vega MI, Garcia-Zepeda EA, Antonio-Andres G, Bonavida B, Riedl M, Kleerup E, Tashkin DP, Hankinson O, Huerta-Yepez S.

Respir Res. 2012 Jul 23;13:60. doi: 10.1186/1465-9921-13-60.

37.

Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival.

Sanchez E, Li M, Kitto A, Li J, Wang CS, Kirk DT, Yellin O, Nichols CM, Dreyer MP, Ahles CP, Robinson A, Madden E, Waterman GN, Swift RA, Bonavida B, Boccia R, Vescio RA, Crowley J, Chen H, Berenson JR.

Br J Haematol. 2012 Sep;158(6):727-38. doi: 10.1111/j.1365-2141.2012.09241.x. Epub 2012 Jul 18.

PMID:
22804669
38.

Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.

Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC.

Cancer Res. 2012 Jun 15;72(12):3091-104. doi: 10.1158/0008-5472.CAN-11-3546. Epub 2012 Apr 13.

39.

TRAF6 activation in multiple myeloma: a potential therapeutic target.

Liu H, Tamashiro S, Baritaki S, Penichet M, Yu Y, Chen H, Berenson J, Bonavida B.

Clin Lymphoma Myeloma Leuk. 2012 Jun;12(3):155-63. doi: 10.1016/j.clml.2012.01.006. Epub 2012 Mar 21. Review.

40.

Galiximab signals B-NHL cells and inhibits the activities of NF-κB-induced YY1- and snail-resistant factors: mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs.

Martinez-Paniagua MA, Vega MI, Huerta-Yepez S, Baritaki S, Vega GG, Hariharan K, Bonavida B.

Mol Cancer Ther. 2012 Mar;11(3):572-81. doi: 10.1158/1535-7163.MCT-11-0635. Epub 2012 Jan 19.

41.

Overexpression of Yin Yang 1 in the pathogenesis of human hematopoietic malignancies.

Bonavida B, Huerta-Yepez S, Baritaki S, Vega M, Liu H, Chen H, Berenson J.

Crit Rev Oncog. 2011;16(3-4):261-7. Review.

PMID:
22248059
43.

Preface: special issue on yin yang 1 and oncogenesis.

Bonavida B.

Crit Rev Oncog. 2011;16(3-4):141-2. No abstract available.

PMID:
22248051
44.

Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer.

Mizutani Y, Katsuoka Y, Bonavida B.

Int J Oncol. 2012 Apr;40(4):1246-50. doi: 10.3892/ijo.2012.1324. Epub 2012 Jan 3.

46.

Lethal iron deprivation induced by non-neutralizing antibodies targeting transferrin receptor 1 in malignant B cells.

Rodríguez JA, Luria-Pérez R, López-Valdés HE, Casero D, Daniels TR, Patel S, Avila D, Leuchter R, So S, Ortiz-Sánchez E, Bonavida B, Martínez-Maza O, Charles AC, Pellegrini M, Helguera G, Penichet ML.

Leuk Lymphoma. 2011 Nov;52(11):2169-78. doi: 10.3109/10428194.2011.596964. Epub 2011 Aug 28.

47.

Mcl-1 and YY1 inhibition and induction of DR5 by the BH3-mimetic Obatoclax (GX15-070) contribute in the sensitization of B-NHL cells to TRAIL apoptosis.

Martínez-Paniagua MA, Baritaki S, Huerta-Yepez S, Ortiz-Navarrete VF, González-Bonilla C, Bonavida B, Vega MI.

Cell Cycle. 2011 Aug 15;10(16):2792-805. Epub 2011 Aug 15.

48.

Expression of phosphorylated raf kinase inhibitor protein (pRKIP) is a predictor of lung cancer survival.

Huerta-Yepez S, Yoon NK, Hernandez-Cueto A, Mah V, Rivera-Pazos CM, Chatterjee D, Vega MI, Maresh EL, Horvath S, Chia D, Bonavida B, Goodglick L.

BMC Cancer. 2011 Jun 21;11:259. doi: 10.1186/1471-2407-11-259.

49.

An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.

Daniels TR, Ortiz-Sánchez E, Luria-Pérez R, Quintero R, Helguera G, Bonavida B, Martínez-Maza O, Penichet ML.

J Immunother. 2011 Jul-Aug;34(6):500-8. doi: 10.1097/CJI.0b013e318222ffc8.

50.

Hypoxia inducible factor promotes murine allergic airway inflammation and is increased in asthma and rhinitis.

Huerta-Yepez S, Baay-Guzman GJ, Bebenek IG, Hernandez-Pando R, Vega MI, Chi L, Riedl M, Diaz-Sanchez D, Kleerup E, Tashkin DP, Gonzalez FJ, Bonavida B, Zeidler M, Hankinson O.

Allergy. 2011 Jul;66(7):909-18. doi: 10.1111/j.1398-9995.2011.02594.x. Epub 2011 Apr 26.

Supplemental Content

Loading ...
Support Center